

Activated Platelet Transfusions Decrease Count Increment and Time to Next Transfusion for Hematology-Oncology Patients

Agnes Pham

University of Colorado, Anschutz Medical Campus



Introduction

- Patients who receive multiple platelet transfusions are at risk of infection, hemolytic and non-hemolytic reactions, and refractoriness
- Platelets have a short shelf life and are often in limited supply
- Patients should receive the fewest number of transfusions necessary to increase their platelets, benefitting patient outcomes and hospital costs
- Microparticles are formed during platelet activation and associated in malignancy, inflammation, infection, and coagulation
- ThromboLUX uses dynamic light scattering to determine microparticle content as a measure of platelet activation status
- The goal of this study was to investigate the effect of activated transfusions on count increment and time between transfusions for hematology/oncology patients following dynamic light scattering testing of platelet concentrates.

Methods

- Platelet units were screened for activation status using ThromboLUX and transfused within 30 hours
- Treating physicians were unaware of the study and activation status of each bag
- Chart review identified eligible hematology-oncology patients based on diagnosis and availability of transfusion data

Results

- 1296 tested platelet components transfused to 122 patients within 90-day study period
- 59 patients and 410 transfusions analyzed for count increment

- **Statistically significant decrease** of $5.4 \times 10^9/L$ (21.5% reduction) in **count increment** after receipt of an activated transfusion
- 54 patients and 416 transfusions analyzed for time between transfusions
- **Statistically significant decrease** of 8.9 hours (30.9% reduction) in **time between transfusions** after receipt of an activated transfusion




Figure 1: Mean count increment before and after transfusion of activated platelets




Figure 1: Mean count increment before and after transfusion of activated platelets

Limitations

- Inconsistent/insufficient documentation excluded portion of eligible patients
- Microparticle content only measure of platelet activation status
- No direct comparison to resting platelet transfusions

Conclusion

- Activated platelet transfusions in hematology/oncology patients reduced count increments and time between transfusions
- Hematology/oncology patients should receive resting platelet concentrates
- Directing platelet concentrates according to resting and activated status may allow for better patient outcomes and improved management of hospital resources.

Acknowledgments

- Dr. Joel Kniep and the UCH transfusion medicine department
- ThromboLUX for provision of instruments
- Darby Thompson for statistical analysis and interpretation of results.

No sources of funding or conflicts of interest

References

- 1.Heddle NM. Febrile nonhemolytic transfusion reactions to platelets. *Curr Opin Hematol* 1995;2: 478-83.
- 2.Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. *Transfusion* 1985;25: 573-7.
- 3.Kiefel V. Reactions Induced by Platelet Transfusions. *Transfus Med Hemother* 2008;35: 354-8.
- 4.Heddle NM, Weibert KE. Investigation of acute transfusion reactions. In: Murphy MF, Pamphilon DH, eds. *Practical Transfusion Medicine*. Oxford: WileyBlackwell, 2009:63-89.
- 5.Hess JR, Trachtenberg FL, Assmann SF, Triulzi DJ, Kaufman RM, Strauss RG, Granger S, Slichter SJ. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. *Vox Sang* 2016;111: 281-91.
- 6.Slichter SJ. Platelet transfusion therapy. *Hematol Oncol Clin North Am* 2007;21: 697-729, vii. Taha M, Kalab M, Yi QL, et al. Bacterial survival and distribution during buffy coat platelet production. *Vox Sanguinis*. 2016;111:333-340. doi: 10.1111/vox.12427.